Literature DB >> 15251671

Effect of intensive insulin therapy on progression of overt nephropathy in patients with type 1 diabetes mellitus.

T T Aoki1, E O Grecu, G M Gollapudi, A R Barber, M A Arcangeli, M M Benbarka, P Prescott, R Meisenheimer.   

Abstract

OBJECTIVE: To assess the effects of chronic (long-term) intermittent intravenous insulin therapy (CIIIT) on the progression of overt nephropathy in patients with type 1 diabetes mellitus.
METHODS: We undertook a retrospective longitudinal three-center study of 31 patients with type 1 diabetes mellitus and overt nephropathy, who were receiving intensive subcutaneous insulin therapy (four insulin injections daily) and weekly CIIIT. All study patients had follow-up consultations weekly for at least 12 months (mean duration, 37.0 +/- 4.6 months). Each patient had monthly hemoglobin A(1c) (by high-performance liquid chromatography) and semiannual creatinine clearance determinations.
RESULTS: The hemoglobin A(1c) levels declined significantly from 8.6 +/- 0.6% to 7.6 +/- 0.3% (P = 0.0062) during the study period. The creatinine clearance remained essentially unchanged (from 46.1 +/- 3.0 mL/min per 1.73 m 2 at baseline to 46.0 +/- 3.9 mL/min per 1.73 m 2 at the end of the observation period, with an average annualized slope increase of 3.39 +/- 1.5 mL/min per year--no significant difference).
CONCLUSION: The addition of CIIIT to intensive subcutaneous insulin therapy in patients with type 1 diabetes mellitus seems to arrest or appreciably reduce the progression of overt diabetic nephropathy, as well as substantially improve their glycemic control.

Entities:  

Year:  1999        PMID: 15251671     DOI: 10.4158/EP.5.4.174

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  1 in total

Review 1.  Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance Pathophysiology.

Authors:  Frank Greenway; Brian Loveridge; Richard M Grimes; Tori R Tucker; Michael Alexander; Scott A Hepford; Justin Fontenot; Candi Nobles-James; Carol Wilson; Adam M Starr; Mohammed Abdelsaid; Stanley T Lewis; Jonathan R T Lakey
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.